Conditions such as fibromyalgia, IBS & Lyme are multi-symptom chronic illnesses that is highly correlated with both intestinal permeability (Leaky-Gut) and SIBO (Small Intestinal Bacterial Overgrowth).
In fact, in one study , Researchers at Cedars-Sinai Medical Center in Los Angeles found that 100% (42/42) of fibromyalgia patients they studied had small intestinal bacterial overgrowth (SIBO).
It is highly rare for a study of this kind to be 100% conclusive.
Another recent study  found that out of 40 patients with fibromyalgia, 28 (70%) had intestinal permeability (i.e. leaky gut). And, 12 of the 28 patients with leaky gut showed no gut symptoms.
Almost half of those patients with leaky gut showed absolutely no symptoms.
Given the concordance of chronic illness with gut abnormalities, multiple researchers have suggested that they may share a common origin.
What is also now well understood is that IBS is characterized by alterations in the gut microbiota, the community of organisms that reside predominately within our GI tracts and significantly influence both our health and well being.
It has been our goal, with the development of Restore 3, to provide a safe and effective therapeutic program that addresses the significant gut dysbiosis that may well play an etiological role in the fibromyalgia and IBS.
Restore 3 simultaneously addresses multiple factors necessary to improve both gut and systemic imbalance, including: nutrient deficiencies, tenacious biofilms, and the need to replenish live probiotic organisms.
Restore 3 contains a specific form of Magnesium, Magnesium Malate. Magnesium Malate has been shown to aid in energy production, and has previously been found to reduce measures of pain in fibromyalgia patients .
The most important discovery that the Restore 3 Program is founded on is the role that biofilm and bacterial overgrowth play in chronically ill patients. If we don’t disrupt the biofilm and eradicate the bacteria overgrowth happening underneath it, we won’t have a fighting chance at ending fibromyalgia.
Furthermore, magnesium deficiency is common in gastrointestinal disorders, and can occur in the setting of SIBO.
Of equal importance, magnesium deficiency has been associated  with intestinal permeability and reductions in microbial diversity. Magnesium, therefore, in addition to its numerous biological functions, is essential to gut integrity.
The Restore 3 formula contains all the elements necessary to address tenacious biofilms that may harbor pathogens and/or may be contributing to an overgrowth of bacteria in the small intestines.
Biofilms consist of a matrix of polysaccharides, proteins, and cations. Restore 3 has been designed with enzymes and compounds to categorically disrupt each of these components. Restore 3 contains enzymes that are capable of dissolving proteins (proteolytic) and polysaccharides (saccharolytic), and are active at the physiological pH found both systemically and within the gut.
Such systemic proteolytic enzymes are measure by ‘HUT,’ an indicator of their ability to dissolve proteins. The proteolytic enzymes within each capsule represent an industry leading quantity of activity, or HUT, to dissolve both fibrin and other biofilm associated proteins.
Furthermore, Restore 3 contains Serrapeptase, a unique proteolytic enzyme, able to reduce the ability of pathogens to attach to host tissues  as well as increasing their susceptibility to antimicrobial compounds.
The EDTA in Restore 3 is essential to bind the ions that are integral biofilm components as well as bind with heavy metals that often become a part of the biofilm matrix. Further, EDTA can reduce biofilm formation and proliferation, can disrupt the cell wall of gram negative bacteria , and can enhance the efficacy of antimicrobials.
Finally, Restore 3 contains Bacillus subtilis, and Bacillus coagulans, two of the most well studied and effective SBO’s (Soil Based Organisms), which are capable of promoting gastrointestinal balance via numerous mechanisms. These organisms can survive the harsh conditions within the stomach and small intestine, and can transiently metabolize and influence the health of the gastrointestinal tract.
Within the gastrointestinal tract Bacillus probiotics can positively modulate the microbiota and provide significant benefits to the host, such as: improved immune function, reduced GI discomfort, improved digestion, and the production of antibacterial and anti-fungal compounds .
Probiotics can also provide significant benefits relative to specific antibiotics in GI disorder like bacterial overgrowth, with less disruption of the endogenous microbiota. In addition, Bacillus subtilis and Bacillus coagulans probiotics, like those in Restore 3, have also been found to possess the following beneficial qualities:
• Production of antimicrobials with activity against many clinically relevant bacterial and fungal pathogens such as: Staphylococcus Aureus, Salmonella Enterica, and Candida Albicans, among others , 
• Increases in beneficial groups of bacteria such as Bifidiobacterium and the intestinal barrier guardian Faecalibacterium Prausnitzii, while decreasing certain species of Clostridium 
• Production of enzymes, such as amylases and proteases, that can improve protein and carbohydrate digestion 
• Increases in Fecal and Salivary IgA, necessary for mucosal immunity, in addition to enhancing the immune response 
• Protection against fungal induced gut barrier dysfunction and stimulation of enhanced tight junction expression, decreasing intestinal permeability 
• Statistically significant improvements in pain and bloating, and disorder specific reductions in colonic inflammation 
- A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing M Pimentel, D Wallace, D Hallegua, E Chow, Y Kong, S Park, H C Lin
- Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G.
- PMCID: PMC3601973 Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part II – contemporary contextual research Alison C Bested, Alan C Logan, and Eva M Selhub
- https://www.ncbi.nlm.nih.gov/pubmed/?term=18479885 Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Longhi C, Scoarughi GL, Poggiali F, Cellini A, Carpentieri A, Seganti L, Pucci P, Amoresano A
- EDTA: An Antimicrobial and Antibiofilm Agent for Use in Wound Care Simon Finnegan1 and Steven L. Percival
- Influence of Bacillus subtilis C-3102 on microbiota in a dynamic in vitro model of the gastrointestinal tract simulating human conditions. Hatanaka M1, Nakamura Y, Maathuis AJ, Venema K, Murota I, Yamamoto N.
- Bacillus subtilis isolated from the human gastrointestinal tract. Hong HA, Khaneja R, Tam NM, Cazzato A, Tan S, Urdaci M, Brisson A
- Anti-candida effect of bacillomycin D-like lipopeptides from Bacillus subtilis B38. Tabbene O1, Kalai L, Ben Slimene I, Karkouch I, Elkahoui S,
- Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Miquel S, Martín R, Lashermes A, Gillet M, Meleine M
- Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine. Maathuis AJ, Keller D, Farmer S.
- Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Lefevre M, Racedo SM, Ripert G, Housez B
- Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis Vibeke Rosenfeldt, MD, PhD, Eva Benfeldt, MD, PhD
- Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS Hun L1